Ophthalmic drug delivery system: Challenges and approaches

Systematic Reviews in Pharmacy

Volumn 1, Issue 2, 2010, Pages 113-120

  Patel, P B ^a   Shastri, D H ^a   Shelat, P K ^a   Shukla, A K ^a  

^a Kalupur Bank Institute of Pharmaceutical Education and Research   (India)

Author keywords

Anterior and posterior segment; Approach; Approaches to improve ocular; Bioavailability; Delivery challenges; Ophthalmic drug delivery; Posterior segment drug delivery

Indexed keywords

EID: 84864020839     PISSN: 09758453     EISSN: 09762779     Source Type: Journal    
DOI: 10.4103/0975-8453.75042     Document Type: Review

References (64)

1. Hughes PM, Mitra AK. Overview of ocular drug delivery and iatrogenic ocular cytopathologies. In: Mitra AK, editor. Ophthalmic Drug Delivery Systems. New York: Marcel Dekker Inc; Vol. 2. 1993. p. 1-27.
2. Lang JC. Recent developments in ophthalmic drug delivery: conventional ocular formulations. Adv Drug Delivery Rev 1995;16:39-43.
3. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv 2004;1:99-114.
4. Hornof M, Toropainen E, Urtti A. Cell culture models of the ocular barriers. Eur J Pharm Biopharm 2005;60:207-25.
5. Anand BS, Dey S, Mitra AK. Current Prodrug strategies via membrane transporters/receptors. Expert Opin Boil Ther 2002;2:607-20.
6. Peyman GA, Ganiban GJ. Delivery systems for intraocular routes. Adv Drug Deliv Rev 1995;16:107-23.
7. Janoria KG, Gunda S, Boddu SH, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 2007;4:371-88.
8. Duvvuri S, Majumdar S, Mitra AK. Drug delivery to the retina: challenges and opportunities. Expert Opin Biol Ther 2003;3:45-56.
9. Keister JC, Cooper ER, Missel PJ, Lang JC, Huger DF. Limits on optimizing ocular drug delivery. J Pharm Sci 1991;80:50-3.
10. Lambert G, Guilatt RL. Current ocular drug delivery challenges. Drug Dev Report Industry Overview Details 2005;33:1-2.
11. Lang JC. Recent developments in ophthalmic drug delivery: conventional ocular formulations. Adv Drug Deliv Rev 1995;16:39-43.
12. Saettone MF, Giannaccini B, Ravecca S, LaMarca F, Tota G. Evaluation of viscous ophthalmic vehicles containing carbomer by slit-lamp fluorophotometry in humans. Int J Pharm 1984;20:187-202.
13. Saettone MF, Giannaccini B, Teneggi A, Savigni P, Tellini N. Evaluation of viscous ophthalmic vehicles containing carbomer by slit-lamp fluorophotometry in humans. J Pharm Pharmacol 1982;3:464-6.
14. Sasaki H, Yamamura K, Mukai T, Nishida K, Nakamura M. Enhancement of ocular drug penetration. Crit Rev Ther Drug Carrier Syst 1999;16:85-146.
15. Saettone F, Giannaccini B, Savigni P. Semisolid ophthalmic vehicles. III. An evaluation of four organic hydrogels containing pilocarpine. J Pharm Pharmacol 1980;32:519-21.
16. Tirucherai GS, Dias C, Mitra AK. Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovir. J Ocul Pharmacol Ther 2002;18:535-48.
17. Lee VH, Carson LW, Kashi SD, Stratford RE. Topical substance P and corneal epithelial wound closure in the rabbit. J Ocul Pharmacol 1986;2:345.
18. Sasaki H, Yamamura K, Mukai T, Nishida K, Nakamura J, Nakashima M, Ichikawa M. Ocular tolerance of absorption enhancers in ophthalmic preparations. Crit Rev Ther Drug Carrier Syst 1999;16:85.
19. Lee VHL. Precorneal, corneal and postcorneal factors. In: Mitra AK (Ed.). Ophthalmic Drug Delivery Systems. New York: Marcel Dekker; 1993. p. 59-82.
20. Sasaki H, Igarashi Y, Nagano T, Yamamura K, Nishida K, Nakamura J. Improvement of the ocular bioavailability of timolol by sorbic acid. J Pharm Pharmacol 1995;47:17-21.
21. Lee VH. Evaluation of ocular anti-inflammatory activity of Butea frondosa. J Contr Rel 1990;11:79-90.
22. Gadbey RE, Green K, Hull DS. Ocular preparations: the formulation approach. J Pharm Sci 1979;68:1176-8.
23. Mitra K. Passive and facilitated transport of pilocarpine across the corneal membrane of the rabbit. Ph.D. Thesis, University of Kansas; Lawrence; KS 1983.
24. Higaki K, Takeuchi M, Nakano M. Estimation and enhancement of in vitro corneal transport of S-1033, A Novel Antiglaucoma Medication. Int J Pharm 1996;132:165-73.
25. Chiou GC, Chuang C. Systematic administration of calcitonin through ocular route. J Pharm Sci 1989;78:815-8.
26. Morimoto K, Nakai T, Morisaka K. (D) Routes of delivery: Case studies: (7) Ocular delivery of peptide and protein drugs. J Pharm Pharmacol 1987;39:124-6.
27. Lee VH. Overview of the ocular drug delivery systems. J Pharm Sci 1983;72:239.
28. Tang-Liu DS, Richman JB, Weinkam JR, Takruri H. Enhancer effects on in vitro corneal permeation of timolol and acyclovir. J Pharm Sci 1994;83:85-90.
29. Nanjawade BK, Manvi FV, Manjappa AS. In situ-forming hydrogels for sustained ophthalmic drug delivery. J Control Release 2007;126:119-34.
30. Kaur IP, Garg A, Singla AK, Aggarwal D. Indian science abstracts. Int J Pharm 2004;1:269.
31. Schaeffer HE, Brietfelter JM, Krohn DL. Vesicular systems: An overview. Invest Ophthalmol Vis Sci 1982;23:530.
32. Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today 2008;13:144-51.
33. Kreuter J, Lenaerts V, Gurny R. In Bioadhesive Drug Delivery Systems. Boca Raton, FL: CRC Press; 1990. p. 203-12.
34. Fitzgerald P, Hadgraft J, Kreuter J, Wilson CG. A γ-scintigraphic evaluation of microparticulate ophthalmic delivery systems: liposomes and nanoparticles. Int J Pharm 1987;40:81-4.
35. MarchalHeussler L, Sirbat D, Hoffman M, Maincent P. Ocular preparation: The formulation approach. Pharm Res 1993;10:386-90.
36. Zimmer K, Kreuter J. Biodegradable polymeric nanoparticles as drug delivery devices. Adv Drug Del Rev 1995;16:61-73.
37. Alonso MJ, Calvo P, VilaJato JL, Lopez MI, Llorente J, Pastor JC. Increased Ocular Corneal Uptake of Drugs Using Poly-e-caprolactone Nanocapsules and Nanoemulsions. In 22nd International Symposium on Controlled Release Bioactive Materials 1995; July 30th-August 4th; Seattle; WA.
38. Pignatello R, Ricupero N, Bucolo C, Zaugeri F, Maltese A, Puglisi G. Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene. AAPS PharmSciTech 2006;7:E27.
39. Ansari MJ, Kohli K, Dixit N. Microemulsions as potential drug delivery systems: a review. J Pharm Sci Technol 2008;62:66-79.
40. Desai SD, Blanchard J. An Encyclopedia of Pharmaceutical Technology In: Swarbrick J, Boylan JC. New York, USA: Marcel Dekker; 1995. p. 43-75.
41. Steinfeld A, Lux A, Maier S, Süverkrüp R, Diestelhorst M. Bioavailability of fluorescein from a new drug delivery system in human eyes. Br J Ophthalmol 2004;88:48-53.
42. Sanzgiri YD, Hume LR, Lee HY, Benedetti L, Topp EM. Ocular sustained delivery of prednisolone using hyaluronic acid benzyl ester films. J Control Release 1993;26:195-201.
43. Cohen S, Lobel E, Trevgoda A, Peled Y. A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye. J Control Release 1997;44:201-8.
44. Joshi A. Recent developments in ophthalmic drug delivery. J Ocul Pharmacol Ther 1994;10:29-45.
45. Doherty MM, Hughes PJ, Kim SR. Effect of lyophilization on the physical characteristics of medium molecular mass hyaluronates. Int J Pharm 1994;111:205-11.
46. Leucuta SE. Microspheres and nanoparticles used in ocular delivery systems. Int J Pharm 1989;54:71-8.
47. Dhaliwal S, Jain S, Singh HP, Tiwary AK. Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation. AAPS J 2008;10:322-30.
48. Jani R, Gan O, Ali Y, Rodstrom R, Hancock S. Ion exchange resins for ophthalmic delivery. J Ocul Pharmacol Ther 1994;10:57-67.
49. Saettone MF, Salminen L. Polymers used in ocular dosage form and drug delivery systems. Adv Drug Deliv Rev 1995;16:95-106.
50. Shell JW. Rheological evaluation and ocular contact time of some carbomer gels for ophthalmic use. Drug Dev Res 1985;6:245-61.
51. Bourges JL, Bloquel C, Thomas A, Froussart F, Bochot A, Azan F, et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev 2006;58:1182-202.
52. Yasukawa T, Ogura Y, Sakurai E, Tabata Y, Kimura H. Intraocular sustained drug delivery using implantable polymeric devices. Adv Drug Deliv Rev 2005;57:2033-46.
53. Bourges JL, Bloquel C, Thomas A, Froussart F, Bochot A, Azan F, et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev 2006;58:1182-202.
54. Marmor MF, Negi A, Maurice DM. Kinetics of macromolecules injected into the subretinal space. Exp Eye Res 1985;40:687-96.
55. Ausayakhun S, Zuvaves P, Ngamtiphakom S, Prasitsilp J. Treatment of cytomegalovirus retinitis in AIDS patients with intravitreal ganciclovir. J Med Assoc Thai 2005;88:S15-20.
56. Bejjani RA, Andrieu C, Bloquel C, Berdugo M, BenEzra D, Behar-Cohen F. Electrically assisted ocular gene therapy. Surv Ophthalmol 2007;52:196-208.
57. Myles ME, Neumann DM, Hill JM. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev 2005;57:2063-79.
58. Parkinson TM, Ferguson E, Febbraro S, Bakhtyari A, King M, Mundasad M. Tolerance of ocular iontophoresis in healthy volunteers. J Ocul Pharmacol Ther 2003;19:145-51.
59. Frucht-Pery J, Raiskup F, Mechoulam H, Shapiro M, Eljarrat-Binstock E, Domb A. Iontophoretic treatment of experimental pseudomonas keratitis in rabbit eyes using gentamicin-loaded hydrogels. Cornea. 2006;25:1182-6.
60. Eljarrat-Binstock E, Raiskup F, Frucht-Pery J, Domb AJ. Transcorneal and transscleral iontophoresis of dexamethasone phosphate using drug loaded hydrogel. J Control Release 2005;106:386-90.
61. Behar-Cohen FF, Aouni A, Gautier S, David G, Davis J, Chapon P, et al. Transscleral Coulomb-controlled iontophoresis of Methylprednisolone into the rabbit eye: influence of duration of treatment current intensity and drug concentration on ocular tissue and fluid levels. Exp Eye Res 2002;74:51-9.
62. Hayden BC, Jockovich ME, Murray TG, Voigt M, Milne P, Kralinger M, et al. Pharmacokinetics of systemic versus focal carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma. Invest Ophthalmol Vis Sci 2004;45:3644-9.
63. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv 2004;1:99-114.
64. Ghate D, Brooks W, McCarey BE, Edelhauser HF. Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry. Invest Ophthalmol Vis Sci 2007;48:2230-7.